ออฟไลน์ด้วยแอป Player FM !
พอดคาสต์ที่ควรค่าแก่การฟัง
สปอนเซอร์
PERCHERON THERAPEUTICS LTD (PER) - Pioneering Rare Disease Treatment: CEO Dr. James Garner on Transformative Duchenne Muscular Dystrophy Therapies, Strategic Evolution, and FDA Collaborations
Manage episode 444572185 series 3570035
Explore the transformative journey of Percheron Therapeutics with Dr. James Garner at the helm, as he shares the company's pioneering efforts in the field of rare disease therapies. Discover how their strategic evolution from Antisense Therapeutics to Percheron Therapeutics has positioned them at the forefront of developing groundbreaking treatments for Duchenne muscular dystrophy (DMD). As we delve into the intricacies of their phase 2b trial of avicursen for non-ambulant boys, Dr. Garner reveals the innovative use of the Performance in the Upper Limb (PUL2.0) endpoint and the promising results from their essential non-human primate toxicology study, aligning with FDA requirements for future clinical trials.
Uncover the strategic blueprint Percheron employs to bring their therapies to market, leveraging Ionis Pharmaceuticals expertise and carefully outsourcing critical tasks, allowing them to concentrate on clinical development. Dr. Garner outlines their ambitious commercialization plans, aiming to partner with larger entities for broader market reach. With pivotal data readouts expected soon and ongoing conversations with the FDA, Percheron is on a mission to de-risk their drugs and attract strong partners. Listen in to understand how these innovative therapies could significantly impact the lives of patients with rare diseases, paving the way for a brighter future.
บท
1. PERCHERON THERAPEUTICS LTD (PER) - Pioneering Rare Disease Treatment: CEO Dr. James Garner on Transformative Duchenne Muscular Dystrophy Therapies, Strategic Evolution, and FDA Collaborations (00:00:00)
2. Developing Therapies for Rare Diseases (00:00:01)
3. Developing and Partnering Drug Therapies (00:12:54)
91 ตอน
Manage episode 444572185 series 3570035
Explore the transformative journey of Percheron Therapeutics with Dr. James Garner at the helm, as he shares the company's pioneering efforts in the field of rare disease therapies. Discover how their strategic evolution from Antisense Therapeutics to Percheron Therapeutics has positioned them at the forefront of developing groundbreaking treatments for Duchenne muscular dystrophy (DMD). As we delve into the intricacies of their phase 2b trial of avicursen for non-ambulant boys, Dr. Garner reveals the innovative use of the Performance in the Upper Limb (PUL2.0) endpoint and the promising results from their essential non-human primate toxicology study, aligning with FDA requirements for future clinical trials.
Uncover the strategic blueprint Percheron employs to bring their therapies to market, leveraging Ionis Pharmaceuticals expertise and carefully outsourcing critical tasks, allowing them to concentrate on clinical development. Dr. Garner outlines their ambitious commercialization plans, aiming to partner with larger entities for broader market reach. With pivotal data readouts expected soon and ongoing conversations with the FDA, Percheron is on a mission to de-risk their drugs and attract strong partners. Listen in to understand how these innovative therapies could significantly impact the lives of patients with rare diseases, paving the way for a brighter future.
บท
1. PERCHERON THERAPEUTICS LTD (PER) - Pioneering Rare Disease Treatment: CEO Dr. James Garner on Transformative Duchenne Muscular Dystrophy Therapies, Strategic Evolution, and FDA Collaborations (00:00:00)
2. Developing Therapies for Rare Diseases (00:00:01)
3. Developing and Partnering Drug Therapies (00:12:54)
91 ตอน
ทุกตอน
×1 AGRIMIN LIMITED (AMN) - Transforming Global Food Security: CEO & Managing Director Debbie Morrow on Mackay Potash Project Breakthroughs, Strategic Export Growth, and Socio-Economic Development in… 10:27
1 MAGNETIC RESOURCES NL (MAU) - Uncovering Gold Mining Secrets: Managing Director George Sakalidis on Laverton Project Success, Strategic Partnerships, and Future Exploration Plans 7:16
1 HAZER GROUP LIMITED (HZR) - Revolutionizing Decarbonization: CEO Glenn Corrie on Methane Pyrolysis Innovation, Strategic Growth, and the Future of Clean Hydrogen Production 18:01
1 VIRIDIS MINING AND MINERALS (VMM) - Transforming Rare Earth Supply Chains: CEO Rafael Moreno on Colossus Project Breakthroughs, Strategic Partnerships, and Sustainable Innovations in South America 9:49
1 CLEVER CULTURE SYSTEMS LTD (CC5) - Revolutionizing Microbiology Laboratories: CEO Brent Barnes on AI-Driven Innovations, Strategic Rebranding, and Global Market Impact 8:49
1 DEXUS CONVENIENCE RETAIL REIT (DXC) - Transforming Real Estate Investment: Fund Manager Jason Weate on Strategic Asset Portfolio, Innovative Capital Recycling, and Future Growth in Australia 13:06
1 RED SKY ENERGY LIMITED (ROG) - Transforming Oil & Gas Business: Managing Director Andrew Knox on Strategic Asset Development, Global Expansion, and Future Growth in Energy Efficiency 8:17
1 NOVA EYE MEDICAL (EYE) - Revolutionizing Glaucoma Treatment: Managing Director Tom Spurling on iTrack™ Innovation, Strategic Global Expansion, and Future Growth Plans 8:19
1 BURGUNDY DIAMOND MINES (BDM)- Revolutionizing the Diamond Industry: CEO Kim Truter on Ethical Sourcing, Strategic Ekati Operations, and the Future Market Outlook 11:23
1 WOTSO PROPERTY (WOT)- Transforming Flexible Workspaces: CEO Jessie Glew on Strategic Suburban Expansion, Revenue Milestones, and Innovative Office Solutions in Australia and New Zealand 7:53
1 WESTERN MINES GROUP (WMG) - Pioneering Nickel Exploration: Managing Director Dr. Caedmon Marriott on Mulga Tank Discoveries, Strategic Development, and Future Market Potential 13:30
1 IONDRIVE LIMITED (ION) - Revolutionizing Battery Recycling: CEO Dr. Ebbe Dommisse on Innovative Eco-Friendly Solutions, Strategic Partnerships, and Global Market Impact 9:24
1 CLEARVUE TECHNOLOGIES LTD (CPV) - Transforming Architecture with Solar Innovation: CEO Martin Deil on Building-Integrated Photovoltaics, Strategic Market Expansion, and the Path to Sustainable… 9:24
1 IR DEPARTMENT - Transforming Investor Relations: Founder & Managing Director Jane Lowe on Strategic AGMs, ESG Priorities, and Future Industry Trends 14:57
1 RESOURO STRATEGIC METALS LTD (RAU) - Revolutionizing Rare Earths: CEO Alistair Stephens on Tiros Project Breakthroughs, Brazilian Expansion, and Dual ASX Listing Strategy 6:08
ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ